Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

614 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Renal function during antihypertensive treatment.
Janssen WM, de Zeeuw D, de Jong PE. Janssen WM, et al. Among authors: de jong pe, de zeeuw d. Lancet. 1995 Jul 15;346(8968):193. Lancet. 1995. PMID: 7661981 No abstract available.
N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk.
Idzerda NMA, Persson F, Pena MJ, Brenner BM, Brunel P, Chaturvedi N, McMurray JJ, Parving HH, de Zeeuw D, Heerspink HJL. Idzerda NMA, et al. Among authors: de zeeuw d. Diabetes Obes Metab. 2018 Dec;20(12):2899-2904. doi: 10.1111/dom.13465. Epub 2018 Aug 5. Diabetes Obes Metab. 2018. PMID: 29987919 Free PMC article. Clinical Trial.
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.
Schievink B, de Zeeuw D, Smink PA, Andress D, Brennan JJ, Coll B, Correa-Rotter R, Hou FF, Kohan D, Kitzman DW, Makino H, Parving HH, Perkovic V, Remuzzi G, Tobe S, Toto R, Hoekman J, Lambers Heerspink HJ. Schievink B, et al. Among authors: de zeeuw d. Eur J Prev Cardiol. 2016 May;23(7):758-68. doi: 10.1177/2047487315598709. Epub 2015 Jul 30. Eur J Prev Cardiol. 2016. PMID: 26229089 Free PMC article. Clinical Trial.
The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.
de Zeeuw D, Bekker P, Henkel E, Hasslacher C, Gouni-Berthold I, Mehling H, Potarca A, Tesar V, Heerspink HJ, Schall TJ; CCX140-B Diabetic Nephropathy Study Group. de Zeeuw D, et al. Lancet Diabetes Endocrinol. 2015 Sep;3(9):687-96. doi: 10.1016/S2213-8587(15)00261-2. Epub 2015 Aug 9. Lancet Diabetes Endocrinol. 2015. PMID: 26268910 Clinical Trial.
Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.
McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D. McMullan CJ, et al. Among authors: de zeeuw d. Am J Kidney Dis. 2014 Nov;64(5):714-22. doi: 10.1053/j.ajkd.2014.06.008. Epub 2014 Jul 24. Am J Kidney Dis. 2014. PMID: 25064674 Clinical Trial.
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.
de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, Perkovic V, Pritchett Y, Remuzzi G, Tobe SW, Toto R, Viberti G, Parving HH. de Zeeuw D, et al. J Am Soc Nephrol. 2014 May;25(5):1083-93. doi: 10.1681/ASN.2013080830. Epub 2014 Apr 10. J Am Soc Nephrol. 2014. PMID: 24722445 Free PMC article. Clinical Trial.
614 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page